Keros Therapeutics (KROS) Misses Q4 EPS by 134c

Keros Therapeutics (NASDAQ: KROS) reported Q4 EPS of ($1.34), $1.34 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $140 thousand versus the consensus estimate of $0 .

For earnings history and earnings-related data on Keros Therapeutics (KROS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• CoStar Group acquires Zonda for $800M, adding new home data